Stemline Therapeutics

Executive Summary

Stemline Therapeutics, a wholly-owned subsidiary of the Menarini Group, is a commercial-stage biopharmaceutical company focused on developing and commercializing innovative oncology therapies. Its lead product, ELZONRIS (tagraxofusp), is the first and only FDA-approved treatment for blastic plasmacytoid dendritic cell neoplasm (BPDCN), a rare and aggressive hematologic malignancy. Since its approval, Stemline has established a commercial infrastructure and is actively exploring label expansion into additional CD123-positive indications, including ongoing clinical trials in acute myeloid leukemia (AML) and other hematologic cancers. The company also maintains a pipeline of early-stage assets, such as MEN1703, a CDK9 inhibitor, and other targeted therapies, though these remain in preclinical or early clinical development. As part of the Menarini Group, Stemline benefits from significant financial resources and a global commercial network, which support its growth strategy. However, the company's heavy reliance on a single approved product exposes it to competitive and regulatory risks, and its pipeline lacks late-stage diversification. Overall, Stemline occupies a niche position in the orphan oncology market with moderate upside potential from label expansion and pipeline progress.

Upcoming Catalysts (preview)

• Q1 2027FDA approval of ELZONRIS for pediatric BPDCN50% success
• Q3 2026Phase 2 data readout for MEN1703 in AML30% success
• TBDStrategic partnership for ELZONRIS commercialization in Japan40% success